55 articles, transcripts, and reports
Merck & Co Inc (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C. Frazier — Chairman of the…
Merck & Co Inc (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C.…
Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged up 5% year-over-year to $12.5…
Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical trials yielded disappointing results. Shares…
Merck (NYSE: MRK) announced the acquisition of privately-held biopharma company OncoImmune for an upfront payment of $425 million in cash with subsequent payments based on…
Merck & Co. Inc. (NYSE: MRK) Q3 2020 earnings call dated Oct. 27, 2020 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C. Frazier — Chairman of…
Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings and sales for the third quarter of 2020. The company’s stock gained early Tuesday…
Merck & Co., Inc. (NYSE: MRK) Q2 2020 earnings call dated July 31, 2020 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations Kenneth C. Frazier — Chairman…
Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of $10.9 billion and adjusted EPS…
Merck & Co (MRK) Q1 2020 earnings call dated April 28, 2020 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations Kenneth C. Frazier — Chairman of the…
